121 related articles for article (PubMed ID: 11741777)
1. Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
Xu G; Hartman TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
Bioorg Med Chem; 2002 Feb; 10(2):283-90. PubMed ID: 11741777
[TBL] [Abstract][Full Text] [Related]
2. Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xu G; Loftus TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Org Chem; 2001 Sep; 66(18):5958-64. PubMed ID: 11529718
[TBL] [Abstract][Full Text] [Related]
3. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
[TBL] [Abstract][Full Text] [Related]
4. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
Casimiro-Garcia A; Micklatcher M; Turpin JA; Stup TL; Watson K; Buckheit RW; Cushman M
J Med Chem; 1999 Nov; 42(23):4861-74. PubMed ID: 10579849
[TBL] [Abstract][Full Text] [Related]
5. Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Cullen MD; Cheung YF; Houslay MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1530-3. PubMed ID: 18222088
[TBL] [Abstract][Full Text] [Related]
6. Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
Milton J; Slater MJ; Bird AJ; Spinks D; Scott G; Price CE; Downing S; Green DV; Madar S; Bethell R; Stammers DK
Bioorg Med Chem Lett; 1998 Oct; 8(19):2623-8. PubMed ID: 9873592
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
Deng BL; Cullen MD; Zhou Z; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
Bioorg Med Chem; 2006 Apr; 14(7):2366-74. PubMed ID: 16321539
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.
Sakamoto T; Cullen MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2007 Jul; 50(14):3314-21. PubMed ID: 17579385
[TBL] [Abstract][Full Text] [Related]
10. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
Cushman M; Casimiro-Garcia A; Williamson K; Rice WG
Bioorg Med Chem Lett; 1998 Jan; 8(2):195-8. PubMed ID: 9871653
[TBL] [Abstract][Full Text] [Related]
12. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
13. Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2006 Aug; 49(17):5316-23. PubMed ID: 16913721
[TBL] [Abstract][Full Text] [Related]
14. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
15. Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Hoshi A; Sakamoto T; Takayama J; Xuan M; Okazaki M; Hartman TL; Buckheit RW; Pannecouque C; Cushman M
Bioorg Med Chem; 2016 Jul; 24(13):3006-3022. PubMed ID: 27234889
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
Silvestri MA; Nagarajan M; De Clercq E; Pannecouque C; Cushman M
J Med Chem; 2004 Jun; 47(12):3149-62. PubMed ID: 15163195
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
Cullen MD; Sarkar T; Hamel E; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Bioorg Med Chem Lett; 2008 Jan; 18(2):469-73. PubMed ID: 18083556
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
Monforte AM; Ferro S; De Luca L; Lo Surdo G; Morreale F; Pannecouque C; Balzarini J; Chimirri A
Bioorg Med Chem; 2014 Feb; 22(4):1459-67. PubMed ID: 24457088
[TBL] [Abstract][Full Text] [Related]
19. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Dunn JP; Li Y; Heilek G; Dunten P; Elworthy TR; Han X; Harris SF; Hirschfeld DR; Hogg JH; Huber W; Kaiser AC; Kertesz DJ; Kim W; Mirzadegan T; Roepel MG; Saito YD; Silva TM; Swallow S; Tracy JL; Villasenor A; Vora H; Zhou AS; Klumpp K
Bioorg Med Chem Lett; 2008 Aug; 18(15):4352-4. PubMed ID: 18632268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
